

研究成果の刊行に関する一覧表(平成 26 年度)

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Tanaka Y</u> , Hirata S, Kubo S, Fukuyo S, Hanami K, Sawamukai N, Nakano K, Nakayamada S, Yamaoka K, Sawamura F, Saito K.	Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.	Ann Rheum Dis	[Epub ahead of print]		
Iwata S, Nakayamada S, Fukuyo S, Kubo S, Yunoue N, Wang S-P, Yoshikawa M, Saito K, <u>Tanaka Y</u> .	Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: A potential target for abatacept therapy.	Arthritis Rheum	[Epub ahead of print]		
Kondo M, Yamaoka K, Sakata K, Sonomoto K, Lin L, Nakano K, <u>Tanaka Y</u> .	IL-6/STAT3 signaling pathway contributes to chondrogenic differentiation of human mesenchymal stem cells.	Arthritis Rheum	[Epub ahead of print]		
<u>Tanaka Y</u> , Hirata S.	Intensive intervention can lead to a treatment holiday from biological DMARD in patients with rheumatoid arthritis.	Drugs	74	2129-2139	2014
Iwata S, Yamaoka K, Niiro H, Jabbarzadeh-Tabrizi S, Wang S-P, Kondo M, Yoshikawa M, Akashi K, <u>Tanaka, Y</u> .	Increased Syk phosphorylation leads to overexpression of TRAF6 in peripheral B cells of patients with systemic lupus erythematosus.	Lupus	(in press)		

<u>Tanaka Y</u> , Martin Mola E.	Can IL-6-targeting catch up TNF-targeting in rheumatoid arthritis: from studies of olokizumab, sarilumab and sirukumab.	Ann Rheum Dis	73	1395-1397	2014
Kubo S, Yamaoka K, Kondo M, Yamagata K, Zhao J, Iwata S, <u>Tanaka Y.</u>	The JAK inhibitor tofacitinib reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.	Ann Rheum Dis	73	2192-2198	2014
Wang S-P, Iwata S, Nakayamada S, Sakata K, Yamaoka K, <u>Tanaka Y.</u>	Tofacitinib, a Jak inhibitor, inhibits human B cell activation in vitro.	Ann Rheum Dis	73	2213-2215	2014
Nakazawa D, Shida H, Tomaru U, Yoshida M, Nishio S, <u>Atsumi T</u> , Ishizu A.	Enhanced formation and disordered regulation of NETs in MPO-ANCA-associated microscopic polyangiitis.	J Am Soc Nephrol	25	990-997	2014
Jin H, Arase N, Hirayasu K, Kohyama M, Suenaga T, Saito F, Tanimura K, Matsuoka K, Ebina K, Shid K, Toyama-Sorimachi N, Yasuda S, Horita T, Hiwa R, Takasugi K, Ohmura K, Yoshikawa H, Saito T, <u>Atsumi T</u> , Sasazuki T, Katayama I, Lanierl LL, Arase H.	Lanierl LL, Arase H. Autoantibodies to IgG/HLA-DR complexes are associated with rheumatoid arthritis susceptibility.	Proc Natl Acad Sci USA	111	3787-3792	2014
Kiyohara C, Washio M, Horiuchi T, Asami T, Ide S, <u>Atsumi T</u> , Kobashi	he modifying effect of NAT2 genotype on the association between systemic lupus erythematosus	Arthritis Care Res	66	1048-1056	2014

G, Takahashi H, Tada Y.	and consumption of alcohol and caffeine-rich beverages.				
Takahashi H, Washio M, Kiyohara C, Tada Y, Asami T, Ide S, <u>Atsumi T</u> , Kobashi G, Yamamoto M, Horiuchi T.	Psychological stress in a Japanese population with systemic lupus erythematosus: Finding from KYSS study.	Mod Rheumato	24	448-452	2014
Fukae J, Tanimura K, <u>Atsumi T</u> , Koike T.	Sonographic synovial vascularity of synovitis in rheumatoid arthritis.	Rheumatology	53	586-591	2014
Amengual O, Horita T, Binder W, Norman GL, Shums Z, Kato M, Otomo K, Fujieda Y, Oku K, Bohgaki T, Yasuda S, <u>Atsumi T</u> .	Comparative analysis of different enzyme immunoassays for assessment of phosphatidylserine-dependent antiprothrombin antibodies.	Rheumatology International	34	1225-1230	2014
Fukae J, Isobe M, Kitano A, Henmi M, Sakamoto F, Narita A, MT,1 Ito T, Mitsuzaki A, Shimizu M, Tanimura K, Matsuhashi M, Kamishima T, MD, <u>Atsumi T</u> , Koike T.	tructural deterioration of finger joints with ultrasonographic synovitis in rheumatoid arthritis patients with clinical low disease activity.	Rheumatology	53	1608-1612	2014
Kono M, Yasuda S, Kato M, Kanetsuka Y, Kurita T, Fujieda Y, Otomo K, Horita T, Oba K, Kondo	Long-term outcome in Japanese patients with lupus nephritis.	Lupus	23	1124-1132	2014

M, Mukai M, Yanai M, Fukasawa Y, <u>Atsumi T.</u>					
Bertolaccini ML, Amengual O, Andreoli L, <u>Atsumi T.</u> , Chighizola CB, Forastiero R, de Groot P, Lakos G, Lambert M, Meroni P, Ortel TL, Petri M, Rahman A, Roubey R, Sciascia S, Snyder M, Tebo AE, Tincani , Willis R .	14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends.	Autoimmun Rev	13	917-930	2014
Kameda H, Miyoshi H, Shimizu C, Nagai S, Nakamura A, Kondo T, Chida D, <u>Atsumi T.</u>	Expression and regulation of neuromedin B in pituitary corticotrophs of male melanocortin 2 receptor-deficient mice.	Endocrinology	155	2492-2499	2014
Devreese KM, Pierangeli SS, de Laat B, Tripodi A, <u>Atsumi T.</u>	Ortel TL; Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH.	J Thromb Haemost	12	792-795	2014
Matsui Y, Tomaru U, Miyoshi A, Ito T, Fukaya S, Miyoshi H, <u>Atsumi T.</u> , Ishizu A.	Overexpression of TNF-alfa converting enzyme promotes adipose tissue inflammation and fibrosis induced by high fat diet.	Exp Mol Pathol	97	354-358	2014
Oku K, Amengual O, <u>Atsumi T.</u>	scoring: significance in diagnosis and prognosis.	Lupus	23	1269-1272	2004

Kurita T, Yasuda S, Oba K, Odani T, Kono M, Otomo K, Fujieda Y, Oku K, Bohgaki T, Amengual O, Horita T, <u>Atsumi T.</u>	The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis.	Rheumatology (Oxford)	in press
Matsuki Y, <u>Atsumi T.</u> , Yamaguchi K, Hisano M, Arata N, Oku K, Watanabe N, Sago H, Takasaki Y, Murashima A.	Clinical features and pregnancy outcome in antiphospholipid syndrome patients with history of severe pregnancy complications.	Rheumatology (Oxford)	in press
Kataoka H, Yasuda S, Fukaya S, Oku K, Horita T, <u>Atsumi T.</u> , Koike T.	Decreased expression of Runx1 and lowered proportion of Foxp3(+) CD25(+) CD4(+)regulatory T cells in systemic sclerosis.	Mod Rheumatol	in press
Kurita T, Yasuda S, Amengual O, <u>Atsumi T.</u>	The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis.	Lupus	in press
Kono M, Yasuda S, Stevens RL, Koide H, Kurita T, Oku K, Bohgaki T, Amengual O, Horita T, Shimizu T, Endo T, Takahata M, Majima T, Koike T, <u>Atsumi T.</u>	RasGRP4 is aberrantly expressed in the fibroblast-like synoviocytes of patients with rheumatoid arthritis and controls their proliferation.	Arthritis Rheum	in press
Nakamura A, Yoneda M, Sumida Y, Miyoshi H, Nakajima A, <u>Atsumi T.</u>	A caution in the use of the NAFIC scoring system as a diagnostic screening tool for nonalcoholic	J Gastroint Dig Syst	in press

Terauchi Y.	steatohepatitis.				
Oku K, Amengual O, Bohgaki T, Horita T, Yasuda S, <u>Atsumi T.</u>	An independent validation of the Global Anti-Phospholipid Syndrome Score in a Japanese cohort of patients with autoimmune diseases.	Lupus	in press		
Nagafuchi H, <u>Atsumi T.</u> , Hatta K, Muso E, Takeno M, Yamada H, Ozaki S.	Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis.	Mod Rheumatol	in press		
Watanabe K, Yasuda S, Noguchi A, Horita T, <u>Atsumi T.</u>	Coronary and mesenteric involvement in polyarteritis nodosa.	Arthritis Rheumatol	in press		
Tamai M, Kita J, Nakashima Y, Suzuki T, Horai Y, Okada A, Koga T, Kawashiri SY, Iwamoto N, Ichinose K, Arima K, Yamasaki S, Nakamura H, Origuchi T, Uetani M, Fukushima A, Aoyagi K, Eguchi K, <u>Kawakami A.</u>	Combination of MRI-detected bone marrow oedema with 2010 rheumatoid arthritis classification criteria improves the diagnostic probability of early rheumatoid arthritis.	Ann Rheum Dis	73	2219-2220	2014
Iwanaga N, Origuchi T, Terada K, Ueki Y, Kamo Y, Kinoshita N, Yonemitsu N, Kawashiri SY, Ichinose K, Tamai M, Nakamura H, <u>Kawakami</u>	Rheumatoid arthritis complicated with severe liver injury during treatment with abatacept.	Mod Rheumatol	24	874-876	2014

<u>A.</u>					
Kawashiri SY, Suzuki T, Nakashima Y, Horai Y, Okada A, Nishino A, Iwamoto N, Ichinose K, Arima K, Tamai M, Nakamura H, Origuchi T, Uetani M, Aoyagi K, Eguchi K, <u>Kawakami A.</u>	Synovial inflammation assessed by ultrasonography correlates with MRI-proven osteitis in patients with rheumatoid arthritis.	Rheumatology (Oxford)	53	1452-1456	2014
Kawashiri SY, Arima K, Suzuki T, Nakashima Y, Horai Y, Okada A, Tamai M, Nakamura H, <u>Kawakami A.</u>	Presence of ultrasound subclinical synovitis and increment of serum vascular endothelial growth factor in a patient with rheumatoid arthritis achieved in sustained clinical remission by treatment with adalimumab and methotrexate.	Mod Rheumatol	24	681-684	2014
Kawashiri S, Ueki Y, Migita K, Nakamura H, Aoyagi K, <u>Kawakami A.</u>	Baseline low modified health assessment questionnaire (MHAQ) predicts the state of remission estimated by clinical disease activity index and MHAQ at 1 year in tocilizumab-treated rheumatoid arthritis patients.	Clin Exp Rheumatol	32	445	2014

Kawashiri SY, Suzuki T, Nakashima Y, Horai Y, Okada A, Iwamoto N, Ichinose K, Tamai M, Arima K, Nakamura H, Origuchi T, Uetani M, Aoyagi K, Eguchi K, <u>Kawakami A.</u>	Ultrasonographic examination of rheumatoid arthritis patients who are free of physical synovitis: power Doppler subclinical synovitis is associated with bone erosion.	Rheumatology (Oxford)	53	562-569	2014
川尻 真也, <u>川上 純</u>	【関節リウマチの診療 身体機能障害をきたさないためのアプローチ】(RAの診断と評価) RAの早期診断はどこまで可能か?	Modern Physician	34	873-877	2014
中村 英樹, <u>川上 純</u>	EULAR2013 改訂 RA 診療 recommendation について	リウマチ科	51	581-589	2014
川尻 真也, 青柳 潔, <u>川上 純</u>	【関節リウマチ-生物学的製剤の登場から 10 年、今後の 10 年-】生物学的製剤 使い方と安全性 エタネルセプト	Mebio	31	24-30	2014
玉井 慎美, 川尻 真也, 上谷 雅孝, <u>川上 純</u>	【関節リウマチ-診断と治療の進歩】早期診断における画像検査の役割	カレントセラピー	32	433-438	2014
玉井 慎美, 上谷 雅孝, 川尻 真也, <u>川上 純</u>	【最新関節リウマチ学-寛解・治癒を目指した研究と最新治療-】関節リウマチの検査・診断 検査 画像検査 関節 MRI、超音波検査	日本臨床	72	253-257	2014
川尻 真也, 青柳 潔, <u>川上 純</u>	RA のマネージメントにおける関節画像診断の利用に関する EULAR recommendation	リウマチ科	51	481-485	2014

一瀬邦弘, <u>川上 純</u>	最新関節リウマチ学 寛解・治癒を目指した研究 と最新治療 .関節リウマチの発症要因と発症メ カニズム Th17 細胞	日本臨床	72	53-58	2014
中村 英樹, <u>川上 純</u>	【リウマチ・膠原病における分子標的治療の最前 線】 IL-1 の作用と臨床効果	最新医学	69	220-225	2014
川尻 真也, <u>川上 純</u>	【関節疾患の画像診断:変形性関節症(OA)と関節リ ウマチ(RA)] 関節リウマチの超音波による評価	映像情報 Medical	46	35-39	2014
<u>川上 純</u> , 川尻 真也, 玉井 慎美, 上谷 雅孝	【関節疾患の画像診断:変形性関節症(OA)と関節リ ウマチ(RA)] 早期関節リウマチの診断と治療戦略	映像情報 Medical	46	1346-1354	2014
<u>上阪 等</u>	最新関節リウマチ学 滑膜線維芽細胞を標的とした 新治療法	日本臨床 72 巻増刊号	3	154-158	2014
<u>上阪 等</u>	最新関節リウマチ学 遺伝子治療	日本臨床 72 巻増刊号	3	717-721	2014
Hosoya T, Iwai H, Yamaguchi Y, Kawahata K, Miyasaka N, <u>Kohsaka H.</u>	Cell cycle regulation therapy combined with cytokine blockade enhances anti-arthritis effects without increase of immune suppression.	Ann Rheum Dis	Published Online First: doi:10.1136/ annrheumdis-2014-205566		
Tahara M, Kondo Y, Yokosawa M, Tsuboi H, Satoru T, Sibayama S, Matsumoto I, <u>Sumida T.</u>	T-bet regulates the differentiation of Foxp3+ regulatory T cells in the deficiency of programmed cell death-1 signaling.	Clin Exp Immunol	in press		

<p>Gazal S, Sacre K, Allanore Y, Teruel M, Goodall AH; (The CARDIOGENICS consortium), Tohma S, Alfredsson L, Okada Y, Xie G, Constantin A, Balsa A, Kawasaki A, Nicaise P, Amos C, Rodriguez-Rodriguez L, Chioccia G, Boileau C, Zhang J, Vittecoq O, Barnetche T, Gonzalez Gay MA, Furukawa H, Cantagrel A, Le Loët X, <u>Sumida T</u>, Hurtado-Nedelec M, Richez C, Chollet-Martin S, Schaefferbeke T, Combe B, Khoryati L, Coustet B, El-Benna J, Siminovitch K, Plenge R, Padyukov L, Martin J, Tsuchiya N, Dieudé P.</p>	<p>Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility gene.</p>	<p>Ann Rheum Dis</p>	<p>Epub ahead of print</p>
<p>Suzuki T, Hirota T, Ogishima H, Umeda N, Kondo Y, Yokosawa M, Miki H, Tsuboi H, Matsumoto I, <u>Sumida T</u>.</p>	<p>Subclinical inflammation with tocilizumab treatment of rheumatoid arthritis: MRI evaluation for 2 years.</p>	<p>Int J Rheum Dis</p>	<p>Epub ahead of print</p>

Yokosawa M, Tsuboi H, Nasu K, Hagiya C, Hagiwara S, Hirota T, Ebe H, Takahashi H, Asashima H, Kondo Y, Ogishima H, Suzuki T, Minami M, Bukawa H, Matsumoto I, <u>Sumida T.</u>	Usefulness of MR imaging of the parotid glands in patients with secondary Sjögren's syndrome associated with rheumatoid arthritis.	Mod Rheumatol	Epub ahead of print		
Hirota T, Suzuki T, Hagiwara S, Ogishima H, Matsumoto I, <u>Sumida T.</u>	Analysis of the usefulness of magnetic resonance imaging evaluation for rheumatoid arthritis treated with biological agents in the early phase: retrospective observation of abatacept and infliximab.	Clin Exp Rheumatol	32(6)	991	2014
Ogishima H, Tsuboi H, Naoto Umeda, Horikoshi M, Kondo Y, Sugihara M, Suzuki T, Matsumoto I, <u>Sumida T.</u>	Analysis of subclinical synovitis detected by ultrasonography and low-field magnetic resonance imaging in patients with rheumatoid arthritis.	Mod Rheumatol	24(1)	60-68	2014
Ikeda K, Seto Y, Natita A, Kawakami A, Kawahito Y, Ito H, Matsushita I, Ohno S, Nishida K, Suzuki T, Kaneko A, Ogasawara M, Fukae J, Henmi M, <u>Sumida T.</u> , Kamishima T, Koike T, JCR-CoSMUS	Ultrasound assessment of synovial pathologies in rheumatoid arthritis using comprehensive multi-plane images of the 2nd metacarpophalangeal joint.	Arthritis Rheum	66(3)	523-32	2014

Tanaka Y, Matsumoto I, Inoue A, Umeda N, Takai C, <u>Sumida T.</u>	Antigen-specific overexpression of human cartilage glycoprotein 39 on CD4+CD25+Foxp3+ Treg cells in the generation of glucose-6-phosphate isomerase induced arthritis.	Clin Exp Immunol	177(2)	419-27	2014
Iizuka M, Wakasa Y, Tsuboi H, Asashima H, Hirota T, Kondo Y, Matsumoto I, <u>Sumida T.</u> , Takaiwa F.	Prophylactic effect of the oral administration of transgenic rice seeds containing altered peptide ligands of type II collagen on rheumatoid arthritis.	Biosci Biotech Bioch	78(10)	1662-8	2014
Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, Iwamoto M, Kohsaka H, Kondo M, Matsubara T, Mimura T, Miyahara H, Ohta S, Saeki Y, Saito K, Sano H, Takasugi K, <u>Takeuchi T.</u> , Tohma S, Tsuru T, Ueki Y, Yamana J, Hashimoto J, Matsutani T, Murakami M, Takagi N.	Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study.	Mod Rheum	2	426-32	2014
Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, <u>Takeuchi T.</u> , Takei S, Tanaka Y, Sano Y, Yamaguchi H, and Yamanaka H.	Characteristics related to good effectiveness and safety with tocilizumab: Post-marketing surveillance of 7901 rheumatoid arthritis patients in Japan.	J Rheumatology	in press		

Nishimoto T, Seta N, Anan R, Yamamoto T, Kaneko Y, <u>Takeuchi T</u> , and Kuwana M.	A single nucleotide polymorphism of TRAF1 predicts the clinical response to anti-TNF treatment in Japanese patients with rheumatoid arthritis.	Clin Exp Rheum	32	211-7	2014
Kurasawa T, Nagasawa H, Kishimoto M, Amano K, <u>Takeuchi T</u> , and Kameda H.	Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: An open, randomized, controlled trial.	Mod Rheum	24	561-6	2014
Yamamoto K, <u>Takeuchi T</u> , Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Shoji T, Sakamaki Y, van der Heijde D, Miyasaka N, and Koike T.	Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.	Mod Rheum	24	715-24	2014
Yamamoto K, <u>Takeuchi T</u> , Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Iwai K, Sakamaki Y, van der Heijde D, Miyasaka N, and Koike T.	Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.	Mod Rheum	24	552-60	2014
Tanaka Y, Yamamoto K, <u>Takeuchi T</u> , Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T,	Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an	Mod Rheum	24	725-33	2014

Miyasaka N, and Koike T.	open-label extension of the HIKARI study.				
Tanaka Y, Yamamoto K, <u>Takeuchi T</u> , Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, and Koike T.	Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study.	Mod Rheum	24	734-43	2014
Tanaka Y, Kubo S, Yamanaka H, Amano K, Hirata S, Tanaka E, Nagasawa H, Yasuoka H, and <u>Takeuchi T</u> .	Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Oencia as Biological Intensive Treatment for RA (ORBIT) study.	Mod Rheum	24	754-62	2014
Yamanaka H, Ishiguro N, <u>Takeuchi T</u> , Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Kupper H, Arora V, and Tanaka Y.	Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial.	Rheumatology	53	904-13	2014
Iwahashi M, Inoue H, Matsubara T, Tanaka T, Amano K, Kanamono T, Nakano T, Uchimura S, Izumihara T, Yamazaki A, Karyekar C, and <u>Takeuchi T</u> .	Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a phase II/III, randomized study.	Mod Rheum	24	885-91	2014

Izumi K, Kaneko Y, Yasuoka H, Seta N, Kameda H, Kuwana M, and <u>Takeuchi T.</u>	Tocilizumab is clinically, functionally and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors. A single center retrospective cohort study (KEIO-TCZ study) at 52 week.	Mod Rheum	25	31-7	2015
Kaneko Y, Kuwana M, Kondo H, and <u>Takeuchi T.</u>	Discordance in global assessments between patient and estimator in patients with newly diagnosed rheumatoid arthritis: associations with progressive joint destruction and functional impairment.	J Rheumatology	41	1061-66	2014
<u>Takeuchi T.</u> , Matubara T, Urata Y, Suematsu E, Ohta S, Honjyo S, Abe T, Yamamoto A, Miyasaka N, and the Japan Abatacept Study Group.	Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate conventional or biologic disease-modifying anti-rheumatic drugs.	Mod Rheum	24	744-753	2014
<u>Takeuchi T.</u> , Matsubara T, Ohta S, Mukai M, Amano K, Tohma S, Tanaka Y, Namanaka H, and Miyasaka N.	Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective multi-center, observational study in Japan. Rheumatology,	Rheumatology	online Sep 24 2014		

<p>Kaneko Y, Koike T, Oda H, Yamamoto K, Miyasaka N, Harigai M, Yamanaka H, Ishiguro N, Tanaka Y, and <u>Takeuchi T</u>.</p>	<p>Obstacles to the implementation of the treat-to-target strategy for rheumatoid arthritis in clinical practice in Japan.</p>	<p>Mod Rheum</p>	<p>25</p>	<p>43-9</p>	<p>2015</p>
<p>Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, <u>Nishimoto N</u>, Kishimoto T.</p>	<p>Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.</p>	<p>J Rheumatol</p>	<p>41(4)</p>	<p>759-767</p>	<p>2014</p>
<p><u>Nishimoto N</u>, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, Iwamoto M, Kohsaka H, Kondo M, Matsubara T, Mimura T, Miyahara H, Ohta S, Saeki Y, Saito K, Sano H, Takasugi K, Takeuchi T, Tohma S, Tsuru T, Ueki Y, Yamana J, Hashimoto J, Matsutani T, Murakami M, Takagi N.</p>	<p>Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study.</p>	<p>Mod Rheumatol</p>	<p>24(1)</p>	<p>26-32</p>	<p>2014</p>

<p><u>Nishimoto N</u>, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, Iwamoto M, Kohsaka H, Kondo M, Matsubara T, Mimura T, Miyahara H, Ohta S, Saeki Y, Saito K, Sano H, Takasugi K, Takeuchi T, Tohma S, Tsuru T, Ueki Y, Yamana J, Hashimoto J, Matsutani T, Murakami M, Takagi N.</p>	<p>Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study.</p>	<p>Mod Rheumatol</p>	<p>24 (1)</p>	<p>17-25</p>	<p>2014</p>
<p>Fujita Y, Fujii T, <u>Mimori T</u>, Sato T, Nakamura T, Iwao H, Nakajima A, Miki M, Sakai T, Kawanami T, Tanaka M, Masaki Y, Fukushima T, Okazaki T, Umehara H</p>	<p>Deficient Leptin Signaling Ameliorates Systemic Lupus Erythematosus Lesions in MRL/Mp-Faslpr Mice</p>	<p>J Immunol</p>	<p>192</p>	<p>979-984</p>	<p>2014</p>
<p>Terao C, Hashimoto M, Furu M, Nakabo S, Ohmura K, Nakashima R, Imura Y, Yukawa N, Yoshifuji H, Matsuda F, Ito H, Fujii T, <u>Mimori T</u></p>	<p>Inverse association between air pressure and rheumatoid arthritis synovitis: an observational study</p>	<p>PLoS ONE</p>	<p>9</p>	<p>e85376</p>	<p>2014</p>

Yamakawa N, Fujimoto M, Kawabata D, Terao C, Nishikori M, Nakashima R, Imura Y, Yukawa N, Yoshifuji H, Ohmura K, Fujii T, Kitano T, Kondo T, Yurugi K, Miura Y, Maekawa T, Saji H, Takaori-Kondo A, Matsuda F, Haga H, <u>Mimori T</u>	A Clinical, Pathological, and Genetic Characterization of Methotrexate-associated Lymphoproliferative Disorders	J Rheumatol	41	293-9	2014
--	---	-------------	----	-------	------

<p>Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Yoshida S, Graham RR, Manoharan A, Ortmann W, Bhangale T, Denny JC, Carroll RJ, Eyler AE, Greenberg JD, Kremer JM, Pappas DA, Jiang L, Yin J, Ye L, Su DF, Yang J, Xie G, Keystone E, Westra HJ, Esko T, Metspalu A, Zhou X, Gupta N, Mirel D, Stahl EA, Diogo D, Cui J, Liao K, Guo MH, Myouzen K, Kawaguchi T, Coenen MJ, van Riel PL, van de Laar MA, Guchelaar HJ, Huizinga TW, Dieudé P, Mariette X, Louis Bridges Jr S, Zhernakova A, Toes RE, Tak PP, Miceli-Richard C, Bang SY, Lee HS, Martin J, Gonzalez-Gay MA, Rodriguez-Rodriguez L, Rantapää-Dahlqvist S, Arlestig L, Choi HK, Kamatani Y, Galan P,</p>	<p>Genetics of rheumatoid arthritis contributes to biology and drug discovery</p>	<p>Nature</p>	<p>506</p>	<p>376-381</p>	<p>2014</p>
---	---	---------------	------------	----------------	-------------

Lathrop M; the RACI consortium;
the GARNET consortium, Eyre S,
Bowes J, Barton A, de Vries N,
Moreland LW, Criswell LA, Karlson
EW, Taniguchi A, Yamada R, Kubo
M, Liu JS, Bae SC, Worthington J,
Padyukov L, Klareskog L, Gregersen
PK, Raychaudhuri S, Stranger BE,
De Jager PL, Franke L, Visscher
PM, Brown MA, Yamanaka H,
Mimori T, Takahashi A, Xu H,
Behrens TW, Siminovitch KA,
Momohara S, Matsuda F, Yamamoto
K, Plenge RM

Tanaka K, Terao C, Ohmura K, Takahashi M, Nakashima R, Imura Y, Yoshifuji H, Yukawa N, Usui T, Fujii T, <u>Mimori T</u> , Matsuda F	Significant association between CYP3A5 polymorphism and blood concentration of tacrolimus in patients with connective tissue diseases	J Hum Genet	59	107-109	2014
Yamamoto N, Yamaguchi H, Ohmura K, Yokoyama T, Yoshifuji H, Yukawa N, Kawabata D, Fujii T, Morita S, Nagata S, <u>Mimori T</u>	Serum milk fat globule epidermal growth factor 8 elevation may subdivide systemic lupus erythematosus into two pathophysiologically distinct subsets	Lupus	23	386-394	2014
Terao C, Yoshifuji H, <u>Mimori T</u>	Recent advances in Takayasu arteritis	Int J Rheum Dis	17	238-247	2014
Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, <u>Mimori T</u> , Soen S, Nagai K, Yamaguchi T, Yamamoto K	Iguratimod-Clinical Study Group: Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: An open-label extension of a randomized, double-blind, placebo-controlled trial	Mod Rheumatol	24	410-418	2014
Hashimoto M, Fujii T, Hamaguchi M, Furu M, Ito H, Terao C, Yamamoto K, Yamamoto W, Matsuo T, Mori M, Ohmura K, Kawabata H, <u>Mimori T</u>	Increase of Hemoglobin Levels by Anti-IL-6 Receptor Antibody (Tocilizumab) in Rheumatoid Arthritis	PLoS ONE	9	e98202	2014
Yokoyama T, Fujii T, Kondo-Ishikawa S, Yamakawa N,	Association between anti-U1 ribonucleoprotein antibodies and inflammatory mediators in	Lupus	23	635-642	2014

Nakano M, Yukawa N, Yoshifuji H, Ohmura K, <u>Mimori T</u>	cerebrospinal fluid of patients with neuropsychiatric systemic lupus erythematosus				
Shiomi A, Usui T, Ishikawa Y, Shimizu M, Murakami K, <u>Mimori T</u>	GM-CSF but not IL-17 is critical for the development of severe interstitial lung disease in SKG mice	J Immunol	193	849-859	2014
Ariyasu H, Iwakura H, Yukawa N, Murayama T, Yokode M, Tada H, Yoshimura K, Teramukai S, Ito T, Shimizu A, Yonezawa A, Kangawa K, <u>Mimori T</u> , Akamizu T	Clinical effects of ghrelin on gastrointestinal involvement in patients with systemic sclerosis	Endocr J	61	735-742	2014
Furu M, Hashimoto M, Ito H, Fujii T, Terao C, Yamakawa N, Yoshitomi H, Ogino H, Ishikawa M, Matsuda S, <u>Mimori T</u>	Discordance and accordance between patient's and physician's assessments in rheumatoid arthritis	Scand J Rheumatol	43	291-295	2014
Nakajima T, Kawabata D, Nakabo S, Miyagawa-Hayashino A, Yukawa N, Yoshifuji H, Ohmura K, Fujii T, <u>Mimori T</u>	Successful treatment with tocilizumab in a case of intralymphatic histiocytosis associated with rheumatoid arthritis	Intern Med	53	2255-2258	2014

Ito Y, Hashimoto M, Hirota K, Ohkura N, Morikawa H, Nishikawa H, Tanaka A, Furu M, Ito H, Fujii T, Nomura T, Yamazaki S, Morita A, Vignali DA, Kappler JW, Matsuda S, <u>Mimori T</u> ; Sakaguchi N, Sakaguchi S	Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease	Science	346	363-368	2014
Ishikawa Y, Usui T, Shiomi A, Shimizu M, Murakami K, <u>Mimori T</u>	Functional engraftment of human peripheral T and B cells and sustained production of autoantibodies in NOD/LtSzscid/IL-2R ^{-/-} mice	Eur J Immunol	44	3453-3463	2014
Shiheido H, Kitagori K, Sasaki C, Kobayashi S, Aoyama T, Urata K, Oku T, Hirayama Y, Yoshitomi H, Hikida M, Yoshifuji H, <u>Mimori T</u> , Watanabe T,	Human T cells expressing BEND3 on their surface represent a novel subpopulation that preferentially produces IL-6 and IL-8	Immun Inflamm Dis	2	35-43	2014
Terao C, Ohmura K, Ikari K, Kawaguchi T, Takahashi M, Setoh K, Nakayama T, Kosugi S, Sekine A, Tabara Y, Taniguchi A, Momohara S, Yamanaka H, Yamada R, Matsuda F, <u>Mimori T</u> ; on behalf of the Nagahama Study Group:	The effects of smoking and shared epitope on the production of ACPA and RF in a Japanese adult population: The Nagahama Study	Arthritis Care Res (Hoboken)	66	1818-1827	2014

Terao C, Ohmura K, Yamada R, Kawaguchi T, Shimizu M, Tabara Y, Takahashi M, Setoh K, Nakayama T, Kosugi S, Sekine A, Matsuda F, <u>Mimori T</u> ; on behalf of the Nagahama Study Group:	An association between anti-nuclear antibody and HLA class II locus and heterogeneous characteristics of staining patterns: The Nagahama Study	Arthritis Rheumatol	66	3395-3403	2014
<u>三森経世</u>	検査・診断: 概論	日本臨床 最新関節リウマチ学 寛解・治癒を目指した研究と最新治療	72	185-189	2014
<u>三森経世</u>	ステロイドの副作用と対策	臨床と研究	91	73-78	2014
<u>三森経世</u>	RA早期診断における自己抗体の役割	CURRENT THERAPY	32	13-18	2014
<u>三森経世</u>	関節リウマチの診療 身体機能障害をきたさないためのアプローチ	Modern Psysician	34	871-872	2014
Katada H, Yukawa N, Urushihara H, Tanaka S, <u>Mimori T</u> , Kawakami K	Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan	Clin Rheumatol	2014 Jan 14. [Epub ahead of print]		
Tsuji H, Yoshifuji H, Fujii T, Matsuo T, Nakashima R, Imura Y, Yukawa N, Ohmura K, Sumiyoshi S, <u>Mimori T</u>	Visceral disseminated varicella zoster virus infection after rituximab treatment for granulomatosis with polyangiitis	Mod Rheumatol	2014 Aug 27. [Epub ahead of print]		

Yang L, Fujimoto M, Murota H, Serada S, Fujimoto M, Honda H, Yamada K, Suzuki K, Nishikawa A, Hosono Y, Yoneda Y, Takehara K, Imura Y, <u>Mimori T</u> , Takeuchi T, Katayama I, Naka T	Proteomic identification of heterogeneous nuclear ribonucleoprotein K as a novel cold-associated autoantigen in patients with secondary Raynaud's phenomenon	Rheumatology (Oxford)	2014 Aug 28. [Epub ahead of print]		
Okada Y, et al(+94 人), <u>Yamamoto K</u> and Plenge RM.	Genetics of rheumatoid arthritis contributes to biology and drug discovery.	Nature	506	376-381	2014
Takeuchi T, <u>Yamamoto K</u> , Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, Koike T.	Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies	Mod Rheumatol	20	1-10	2014
Kochi Y, Suzuki A, <u>Yamamoto K</u> .	Genetic basis of rheumatoid arthritis: a current review	Biochem Biophys Res Commun	452	254-62	2014